搜索
Fractyl Health Inc
GUTS添加自选
0.861USD
-0.093-9.79%
收盘 05/15, 16:00（美东）报价延迟15分钟
136.53M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-9.79%
5天
+14.03%
1月
+67.30%
6月
-31.70%
今年开始到现在
-60.88%
1年
-49.08%
TradingKey Fractyl Health Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Fractyl Health Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名102/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.24。中期看，股价处于上升通道。近一个月，市场表现很强，基本面评分较高，但很强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Fractyl Health Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Fractyl Health Inc亮点
亮点风险
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-0.46，处于3年历史高位
机构加仓
最新机构持股126.15M股，环比增加15.59%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值1.86M
分析师目标
根据
5
位分析师
买入
评级
5.240
目标均价
+449.27%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Fractyl Health Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Fractyl Health Inc简介
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
公司代码GUTS
公司Fractyl Health Inc
CEORajagopalan (Harith)
网址https://www.fractyl.com/
相关品种
